Jivi

Damoctocog alfa pegol, the active ingredient in Jivi, is a recombinant factor VIII product presented as a solution for injection for intravenous use. It replaces deficient factor VIII in patients with hemophilia A, helping to control and prevent bleeding episodes. The therapy is used for routine prophylaxis, on‑demand treatment of bleeding events, and peri‑operative management of individuals with congenital factor VIII deficiency.

GNH USA supplies Jivi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Jivi, a recombinant factor VIII concentrate, acts on the intrinsic coagulation pathway to replace deficient factor VIII in hemophilia A. - Hemophilia A (congenital factor VIII deficiency): provides factor VIII replacement to prevent or control spontaneous and traumatic bleeding. - Perioperative management of hemophilia A: maintains adequate hemostasis during surgical procedures. - On‑demand treatment of bleeding episodes in hemophilia A: rapidly restores clotting ability to stop active bleeds.

Jivi may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the infusion site - Headache: transient mild to moderate pain - Fever: low-grade temperature rise - Arthralgia: joint pain without swelling - Nausea: occasional upset stomach - Fatigue: general tiredness - Dizziness: brief light‑headed sensation - Mild rash: limited skin redness

Serious or Rare Side Effects: - Development of inhibitory antibodies: neutralizing factor VIII activity - Anaphylactic or severe allergic reactions: rapid onset breathing difficulty and hives - Thromboembolic events: clot formation in veins or arteries - Disseminated intravascular coagulation: widespread clotting and bleeding - Hemolysis: destruction of red blood cells - Severe hypotension: marked drop in blood pressure

When using Jivi, several precautions should be observed to ensure safety and efficacy. - Monitor for inhibitor development: test for anti‑factor VIII antibodies regularly. - Assess for allergic reactions: watch for rash, itching, or respiratory symptoms during infusion. - Use with caution in patients with a history of thrombosis: evaluate clotting risk before administration. - Avoid in individuals with known hypersensitivity to any component of the product: confirm allergy history. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Jivi can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Concurrent use of other factor VIII concentrates: may increase risk of inhibitor formation. - Immunosuppressive agents that alter immune response: could affect antibody development.

Moderate Interactions (Monitor Closely): - Heparin or low‑molecular‑weight heparin: monitor coagulation parameters. - Antiplatelet drugs (e.g., aspirin, clopidogrel): increased bleeding risk. - Antifibrinolytics (e.g., tranexamic acid): may enhance clot stability, watch for thrombosis. - Live vaccines: potential altered immune response.